3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Seminoma
2
Ovarian Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Hodgkin Disease
2
Vulvar Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Skin Neoplasms
1
Ovarian Germ Cell Cancer
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Gynecological Cancers
1
Endodermal Sinus Tumor
1
Carcinoma, Embryonal
1
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
6
cemiplimab
4
aldesleukin
3
Interleukin-2
3
fludarabine
2
Specimen Handling
2
Niacinamide
2
HhAntag691
2
Cyclophosphamide
2
Blood Specimen Collection
2
Biopsy
2
trametinib
1
spartalizumab
1
sonidegib
1
pertuzumab
1
lifileucel
1
four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate)
1
fludarabine phosphate
1
dabrafenib
1
brodalumab
1
atezolizumab
1
Vitamin A
1
Trastuzumab
1
Tissue Banks
1
Surgical Procedures, Operative
1
Sunscreening Agents
1
Standard of Care
1
Second Harmonic Generation Microscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Skin Neoplasms
×
Bleomycin
×
Clear all
NCT06647342
2025-01-23
BLESS
Zealand University Hospital
Phase 4
Recruiting
55 enrolled